Ipca Laboratories Q4 FY26 Earnings Call — Analysis (NSE: IPCALAB)

Ipca Labs posted FY26 consolidated revenue growth of 8% to ₹9,646 Cr with EBITDA margin expanding to 20.72%, guiding for 12-13% topline growth and 22-22.3% EBITDA margin in FY27.

1 Jun 2026 · Analysis by Alpha Inflection

Result quality: stable — Results context unavailable. Management sentiment: optimistic.

The take

FY26 Consolidated Revenue ₹9,646 Cr ( +8% YoY ) . New guidance — FY27 consolidated revenue growth 12% to 13% . New story: Domestic Brand Focus and Pricing Power .

Results

Q4FY26 consolidated revenue rose 6% YoY to ₹2,388 Cr with EBITDA margin improving 228 bps YoY to 20.52%; FY26 revenue reached ₹9,646 Cr (+8% YoY) with EBITDA margin at 20.72% (+178 bps YoY).

Financial highlights

Guidance

FY27 consolidated revenue is guided to grow 12-13% YoY in INR terms with consolidated EBITDA margins expected to expand to 22.0-22.3%.

What management committed to

• Overall company as a whole, including [Unichem Laboratories], should deliver around 12% to 13% revenue growth on a consolidated basis in [FY27]. — 12% to 13%, FY27
• On consolidated EBITDA side, from 20.7% currently, [EBITDA margin] should reach almost around 22% or 22.3% in [FY27]. — 22% or 22.3%, FY27
• [Unichem Laboratories] US business should grow by around 10% in [FY27]. — around 10%, FY27
• [Unichem Laboratories] EBITDA margin may become around 12% to 13% in [FY27]. — around 12% to 13%, FY27
• [Pisgah Labs] formulation facility under construction in US will be ready to commission in [Q4FY27]. — Q4FY27
• Ipca will launch around 6 to 8 generic products in the US in [FY27]. — 6 to 8 products, FY27
• Unichem should launch at least 5 to 6 products in the US market in [FY27]. — 5 to 6 products, FY27
• Overhead expenditure of EUR 4 million to EUR 5 million at the Ireland facility will stop in [FY27]. — EUR 4 million to EUR 5 million, FY27

Key themes

Margin expansion and domestic-export formulation recovery

How the narrative shifted

• Domestic Brand Focus and Pricing Power: Ipca prioritises 2-3 power brands per division and takes selective 6-7% price hikes in decontrolled domestic portfolios to fully offset input cost pressures.
• Unichem Turnaround and Cost Rationalisation: Shutting Ireland operations, repatriating manufacturing to India, and switching from air to sea freight will expand Unichem margins to 12-13% in FY27.
• Input Material Inflation and Geopolitical Freight Disruption: Solvent, chemical, and packaging costs rose 10-12% alongside a 25% freight spike due to Middle East tensions, causing management to slightly moderate margin guidance.
• US Pipeline and Institutional Expansion: Steady rollout of 11-14 combined launches across Ipca and Unichem plus tech transfers for US institutional manufacturing are creating incremental growth engines.

Operational commentary

• Unichem shut down its Ireland manufacturing facility, incurring severance and restructuring costs in FY26 while transferring production back to India, saving €4m to €5m in annual overheads.
• Unichem shifted logistics mode from air freight (~40% a year ago) to ocean shipping (now only 4-5% air freight), normalizing freight cost structure despite lengthening transit inventory.
• Pisgah Labs (US subsidiary) is constructing a formulation facility scheduled for commissioning in Q4FY27, with meaningful revenue contribution anticipated starting FY28.
• Unichem initiated technology transfers for 4 to 5 products to US third-party manufacturers to target US institutional/government supply opportunities, adding ₹10-12 Cr in R&D costs in Q4FY26.
• Domestic market share marginally improved to 2.09% in MAT March 2026 (from 2.08% in MAT Dec 2025), holding rank 16 with 6 brands among top 300.
• Krebs Bio's Nellore plant turned EBITDA positive, while issues at the polishing department in the other facility are being addressed.

Analyst Q&A

• Q. How many molecules need to be launched per year to sustain 15-20% growth over 2-3 years, and what is the pipeline for Q1/Q2 FY27?

  Ipca focuses on power brands rather than heavy product launches, planning 18-20 domestic products across 20 divisions, 6-8 US generic launches for Ipca, 5-6 US launches for Unichem, and 3-4 launches per European market annually.

• Q. Why is inventory at Unichem still elevated despite stated remedial actions?

  Shift from air freight (previously ~40%) to sea shipment (now 4-5%) lengthened transit time and transit inventory, but working capital across the core Ipca business remains tightly managed with no incremental capital absorbed.

• Q. Will Lyka Labs face an impairment write-down similar to Krebs Bio given deteriorating performance?

  Management declined to comment in detail on Lyka Labs as an independent associate company, noting only that investments in field force for animal health and critical care are depressing near-term margins but progressing well.

• Q. What is driving the sharp increase in input raw material and freight costs and how will margins hold up?

  Input raw material prices (solvents, packaging, APIs) rose 10-12% and freight rose 25% in Q4 due to geopolitical disruptions, but because raw material costs are only ~25% of sales, 6-7% price hikes in domestic decontrolled products and full pass-through in APIs will protect EBITDA margin expansion to 22-22.3%.

Research and educational content only. Not investment advice.